Combination of Neostigmine and Metoclopramide to reduce gastric residual volume in mechanically ventilated ICU patients

The effect of combination of Neostigmine and Metoclopramide on gastric residual volume in mechanically ventilated ICU patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201408104365N16

Enrollment

Registered

2015-01-01

Start date

2014-03-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The relation of combination of Neostigmine and Metoclopramide with gastric residual volume in mechanically ventilated ICU patients.

Interventions

Intervention 1: Intrvention group 1: Neostigmine 2.5 mg in 100 ml normal saline infused during 30 minute at the beginning of trial. Intervention 2: Intrvention group 2: Metoclopramide 10 mg in 100 ml

Treatment - Drugs

Intrvention group 1: Neostigmine 2.5 mg in 100 ml normal saline infused during 30 minute at the beginning of trial

Intrvention group 2: Metoclopramide 10 mg in 100 ml normal saline infused during 30 minute at the beginning of trial

Intrvention group 3: Neostigmine 2.5 mg + Metoclopramide 10 mg in 100 ml normal saline infused during 30 minute at the beginning of trial

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patient family agreement and informed written consent; under mechanical ventilation; nutrition via gastric tube; gastric residual volume greater than 120 cc; age between 20 and 60 years Exclusion criteria: diabetes; heart rate1.5 in two consecutive test); prokinetic agents consumption during 8 hours before intervention; recent surgery on GI tract within 10 days; pregnancy and breast feeding; extrapyramidal sign; bronchospasm; hypokalemia (K<3 meq/L); known sensitivity to Neostigmine and metoclopramide; GI bleeding.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Gastric residual volume. Timepoint: 0,3,6,9,12 hours after intervention. Method of measurement: Gastric lavage.	—

Secondary

Measure	Time frame
Albumin, hemoglobin, WBC, Na, K, Mg. Timepoint: Before trial. Method of measurement: laboratory kit.;Hear rate, blood pressure. Timepoint: During trial. Method of measurement: Cardiac monitoring.;SOFA. Timepoint: before trial. Method of measurement: SOFA calculator.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAfshin Gholipour Baradari, MD

Mazandaran University of Medical Sciences

gholipourafshin@mazums.ac.ir; gholipourafshin@yahoo.com+98 11332612458

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026